Overview

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

Status:
Recruiting
Trial end date:
2029-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC